Approximately 50% of older patients with acute myeloid leukemia (AML) do not obtain chromosomal abnormalities as an effective risk-stratification, and present cytogenetically normal AML (CN-AML). To develop a reliable prediction model for stratifying the risk of these elderly patients, we conducted a study with a discovery and validation design. As a result, we found the top 6 mutated genes in the discovery cohort of 26 case by the whole exome sequencing, and verified as recurrent mutations in the large cohort of 329 patients by Sanger sequencing. The top 6 genes were NPM1, FLT3-ITD, DNMT3A, CEBPA double allele, IDH1 and IDH2 mutations, and the frequency of each gene in the combining cohort was 36.8%, 19.8%, 20.1%, 5.8%, 14.9% and 22.5%, respectively. In addition, clinical variables such as age, white blood cell counts, genes of IDH1 and DNMT3A mutations, European LeukemiaNet genotype (NPM1 mutations and lacking FLT3-ITD or CEBPA double allele mutations) and treatment protocols were independent factors for predicting the probabilities of overall and event-free survival. The prediction nomograms based on these significant factors showed accurate discrimination. In conclusion, we developed a reliable prediction model for stratifying the risk of elderly patients with CN-AML.
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Background
With a longer life expectancy, the incidence of acute myeloid leukemia (AML) is rising in the aging population. However, while the outcome of younger (<60 years) patients has improved over the last four decades, very little progress has been made for older (60 years) patients, whose long-term overall survival (OS) remains very poor (<10%). 1 The dismal outcome in this age group may be explained by increased frequencies of high risk clinical and genetic features (i.e., secondary and therapy-related (t-) AML, adverse cytogenetic and molecular aberrations), co-morbidities, inability for tolerating intensive treatment and lack of suitable donors for allogeneic hematopoietic stem cell transplantation (allo HSCT).
Although chromosomal abnormalities have been validated as an effective risk-stratification tool, approximately 50% of older patients with AML have normal karyotypes when assessed by standard cytogenetic analysis. The outcome risk for these cytogenetically normal (CN) patients is currently defined using a combination of at least three molecular biomarkers: NPM1 and CEBPA mutations and FLT3-ITD.
2,3
However, a plethora of additional biomarkers is emerging and they may also be used to further refine molecular risk definition. Among these markers are the mutations in gene encoding epigenetic modifiers (e.g., IDH1, IDH2, DNMT3A mutations), which in some studies, but not in others, have been shown to impact the outcome of the older patients. [4] [5] [6] Interestingly, while the majority of the studies have focused on cohorts of patients from Western countries, very little is known on the impact of these mutations in the Eastern Asian population that arguably represents a very large proportion of the world populations. 4, 5, [7] [8] [9] Here, we identified the frequently mutated genes by whole-exome sequencing (WES) and validated in a large cohort of elderly patients with cytogenetically normal AML. Moreover, we conducted a reliable prediction nomogram for individual patient risk stratification.
Material and Methods

Patients
The study used a discovery and validation design. The training cohort consisted of 26 elderly CN-AML patients with available high quality samples used to determine gene mutation profiling by the WES. Three hundred and three consecutive older patients [age, median (range): 67 (60-89) years; female/male: 144/185] with primary CN-AML treated at the Zhejiang Institute of Hematology (ZIH; Hangzhou, China) from 2008 to 2014 were analyzed to validate the frequently mutated genes identified in the training cohort. Bone marrow (BM) samples were obtained at the time of diagnosis. To be considered cytogenetically normal, at least 20 metaphase cells from diagnostic BM had to be evaluated by standard banding cytogenetic analysis. Patients received anthracycline and cytarabine induction chemotherapy, and consolidations chemotherapy based on the treating physician's choice in an individualized manner. Details of the treatment protocols were provided in the supplementary material. All of the subjects provided written informed consent to participate in the study. The study was approved by the Institutional Review Board of the First Affiliated Hospital of Zhejiang University.
Cytogenetic and gene mutation analysis
Cytogenetic and molecular studies were performed centrally at ZIH molecular laboratories. Mononuclear cells were isolated from the BM samples by Ficoll-Hypaque density-gradient centrifugation and DNA and RNA were extracted as described previously. 10 Mutation analyses of NPM1, FLT3-ITD, CEBPA, DNMT3A, IDH1 and IDH2 were carried out as described previously.
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Whole exome sequencing
Methods used in the WES analysis are described in the supplementary data.
Statistical analyses
The discrete variables of patients were compared using the v 2 tests or Fisher's exact test. A nonparametric test was used to compare continuous variables and medians of distributions.
The main objective of our study was to identify the gene mutations panel and its prognostic significance in elderly patients with CN-AML. Overall survival (OS) was defined as time from date of diagnosis until death due to any cause or the last follow-up, and event-free survival (EFS) was defined as time from date of diagnosis until removal from study due to non-complete remission, relapse or death. Univariate and multivariate analyses using Cox proportional hazard regression models were conducted to determine the independent prognostic value of gene mutations on OS and EFS. The proportional hazards assumption was checked for each significant variable when Cox regression models were constructed. Clinically important variables associated with OS and EFS were evaluated for inclusion into the nomogram. The association of relevant predictors with OS and EFS were assessed using Cox proportional hazards model. Backward stepwise selection with the Akaike information criterion (AIC) was used to identify variables for the multivariate analyses models. Selected variables were then incorporated into the nomogram. Model performance was evaluated by assessing discrimination with Harrell's C-index, calibration plots using a bootstrapped sample and plotting Kaplan-Meier curves over the quartiles of prediction by nomogram. All statistical analyses were conducted with R statistic packages, version 3.1.2 (www.r-project.org). p < 0.05 demonstrated statistical difference.
Results
Identification of the frequently mutated genes by WES
We performed WES of bone marrow blasts from 26 elderly patients with CN-AML as the training cohort. Clinical characteristics are summarized in Table 1 . We discovered 163 somatic single-nucleotide variants (SNVs) and 29 small insertions and 18 deletions in the exome regions, with a median of 8 mutations per sample and a range from 2 to 19 ( Fig.  S1 ). A total of 91 mutated genes were found in these samples. The mutated genes are involved in the 78 GO functions including chromatin binding (GO:0003682), structure-specific DNA binding (GO:0043566), transcription factor binding (GO:0008134), etc. (Table S1 ). Notably, the top 7 genes were well-established genes like NPM1 (42%), IDH2 (38%), FLT3 (31%), DNMT3A (23%), IDH1 (23%), CARL (19%) and CEBPA (19%) (Fig. 1) . Consistently, when we verified these well-established genes of NPM1, IDH2, IDH1, DNMT3A, FLT3 and CEBPA by Sanger sequencing in the same 26 samples, the mutation rate of each of the genes was 42.3%, 38.5%, 23.1%, 26.9%, 19.2% and 7.7%, respectively. As shown in Table S2 , the disparity of the results between those obtained with WES and Sanger sequencing was predominant in genes with less common mutation in older patients like
What's new?
Overall survival for older patients with acute myeloid leukemia (AML) is generally poor. Certain genetic mutations are correlated with prognosis in younger patients; however, it is not known whether these associations also apply to elderly patients. In our study, the authors identified and validated a pattern of specific mutations that are associated with prognosis in elderly patients, including those of Asian origin. They then developed a precise and simple nomogram to translate these molecular and clinical data into a reliable prediction model for stratifying risk for these patients.
CEBPA double allele mutations, FLT3 and CALR but not in the top 2 genes like NPM1 and IDH2 mutations. Specifically, for five patients with CEBPA mutations (5/26, 19%) determined by WES, only three patients with CEBPA mutations were verified with Sanger sequencing. Among these three patients, two patients had CEBPA double allele mutations. In addition, there are two cases with FLT3-ITD, three cases with FLT3-TKD, and the remaining three cases with the less common mutations of FLT3 point mutations determined by WES. However, these less common point mutations were not verified by Sanger sequencing (Table S2) . With respect to CARL mutations, we can only verify one out of five mutated samples, and did not identify this gene mutation again in an additional 120 samples.
Validation of the interesting genes in the elderly CN-AML patients
We further enrolled 303 elderly patients with CN-AML to measure the mutation status of each gene by Sanger sequencing. The detailed characteristics of patients are summarized in Table 1 . As a result, the rate of mutation in the top 6 genes was respectively comparable to those in the training dataset. There was no significant difference for each frequency of the six genes, so we collectively analyzed each frequency of these genes in the combining cohort. As summarized in Table 1 reported in other studies, 8 ,11 a pattern of co-occurrence of FLT3-ITD, DNMT3A, IDH and NPM1 mutations occurred in our study, which was reflected in the significant correlation among these genes. By contrast, a negative correlation between CEBPA double allele and genes FLT3-ITD, IDH2 and IDH1 mutations was also found (Fig. S2) . The pattern of co-mutations largely shapes clinical outcome.
Prognostic significance of the top 6 mutated genes in the elderly patients
The CR rate, 3-year OS and EFS rates for the entire cohort of 329 patients was 54%, 26% and 19%, respectively. In univariable analyses, patients with older age, higher white blood cell counts (WBC), and genes of IDH1, FLT3-ITD and DNMT3A mutations were associated with lower CR rate, shorter OS and EFS durations (Fig. 2, Table S3 ), respectively. While those with CEBPA double allele mutations, European LeukemiaNet (ELN) favorable genotype (i.e., mutated NPM1 without FLT3-ITD and CEBPA double allele mutations, Fig.  2 ) had a longer OS or EFS durations compared to the respective wild type counterparts. However, patients with IDH2 mutations had a trend for favorable outcome, but differences did not reach statistical significance (Fig. S3) . In multivariate analyses, age, WBC, ELN favorable genotype, and genes of DNMT3A and IDH1, but not IDH2 mutation were independent prognostic factors ( Table 2) .
Nomogram of clinical and molecular factors for stratifying the risk of patients
The resulting coefficients from the Cox regression models were used to construct the nomograms for OS and EFS. The variables were developed based on the independent predictors including age, WBC, ENL genotype, DNMT3A and IDH1 mutation, and treatment protocols. Each factor in the nomogram was assigned a weighted score. By adding up the total score from all the variables from individual patients and locating it on the total point scale, we could determine the probabilities of OS (Fig. 3) and EFS (Fig. S4) by drawing a vertical line to the total score. Discrimination ability of the final models was assessed by the 80-resample bootstrapped calibration plots for the prediction of 3-year OS and EFS (Fig. S5) . The calibration plots revealed good prediction of 3-year OS and EFS.
Discussion
Elderly patients with CN-AML generally had poor outcomes in part due to the limited information available for risk stratification. In our study, we identified and focused on the most frequently mutated genes in elderly patients with CN-AML by WES, and validated the six genes (FLT3-ITD, CEBPA, NPM1, DNMT3A, IDH1 and IDH2) in a large independent cohort by Sanger sequencing. Furthermore, we developed a prediction nomogram for individual patients.
With the advances of next-generation sequencing (NGS) technologies, the genetic variants had been comprehensively described in adult unselect AML 12 or non-M3 AML 11 or AML with FAB M4/5 phenotype, 13 and few studies focused on elderly patients with CN-AML. Current treatment is riskadapted, predominantly based on gene mutations. Because NGS technology enables parallel analysis of many genes, NGS could be used to define a new genetic mutation profile to serve as a prognostic panel in the elderly CN-AML patients. To identify the panel of mutated genes, we designed our study using the training and validation strategy. First, we performed the WES in 26 elderly patients with CN-AML to investigate whether novel genetic mutations can be identified. As expected, we found NPM1, FLT3, DNMT3A, CEBPA, CARL, IDH1 and IDH2 as the top 7 mutated genes. Among these genes, CARL mutation (19%, 5 out of 26) was not reported as the common mutation in AML. Unfortunately, only one patient with CARL mutation was verified by Sanger sequencing in the five mutated cases previously determined by WES, and did not occur in an additional 120 elderly patients with CN-AML. It seemed that over-diagnosis of CEBPA double allele and FLT3 mutations occurs with NGS. The reason might be the fact repeated sequences can be misassembled by NGS. 14 In fact, CEBPA double allele mutations are typically on different alleles, which involves a combination of N-terminal and C-terminal basic leucine zipper (bZIP) gene mutation. 15 Notably, mutations in the Cterminal bZIP region exhibit in-frame duplications. 15 Therefore, over-diagnosis with NGS of CEBPA mutations will appear in our study. With respect to FLT3 mutations, the two major types of mutation are internal tandem duplication (ITD) mutations of the juxtamembrane region and point mutations in tyrosine kinase domain (TKD), which frequently involve aspartic acid 835 of the kinase domain (D835). In addition, point mutations have been scarcely found in the codons within the kinase domain and juxtamembrane region. In the training cohort of 26 cases, we found three cases with the less common mutations of FLT3. However, these less common mutations were not verified by Sanger sequencing (Table S2) . Because the prognostic impact of FLT3-TKD remains unknown, we did not test FLT3-TKD mutation status in the validated cohort. Thus, the top 6 genes like FLT3-ITD, CEBPA, NPM1, DNMT3A, IDH1 and IDH2 were verified by Sanger sequencing both in the training set of 26 cases and in the independent cohort of 303 patients. Although a higher ratio of each gene mutations seemed to occur in the training set than in the validation set, the difference was not significant. Therefore, we combined the two data sets into one data for exploring the frequency and prognostic value of these genes. Subsequently, NPM1 mutations represented the most frequent mutation in AML and could be detected in 36.8% of elderly patients in our study. This result is nearly identical with the data presented by Sebastian Scholl.
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FLT3-ITD mutations were reported as the second most frequent molecular aberration in AML. 17 Here we found 19.8% cases with FLT3-ITD positive. The incidence of 5.8% CEBPA in our patients was similar to the 4% incidence reported in recent studies of older patients with intermediate risk cytogenetics. 18 The percentage of elderly CN-AML patients carrying a DNMT3A mutation was 20.1%, which is also consistent with the data in a previous study. 12 In our study, we found the frequency of IDH2 (22.5%) mutations was higher than those of IDH1 (14.9%) mutations. The underlying reason might be that IDH2 but not IDH1 mutations were associated with older age. 5 Recently, several other genetic alterations like TP53, RUNX1 and ASXL1 mutations were found to be more prevalent in the elder population. 11 However, we did not observe these genes as commonly mutated genes, the reason might be a difference in population. Taken together, we found six frequent mutations of genes in our elderly patients with CN-AML.
Reliable estimation of the risk of recurrence and death following chemotherapy is important to both physicians and patients. In our survival analyses, we found age, WBC, treatment protocols, ELN genotype and genes of DNMT3A, IDH1 but not IDH2 mutations could be used as independent predictors. Because European LeukemiaNet (ELN) genotype was proposed as a standardized classification in the elderly patients with CN-AML, 18 we used ELN genotype but not individual genes (FLT3-ITD, NPM1 and CEBPA) as a potential predictor in the multivariate models. To establish precision medicine for every patient, previous studies utilized 8-10 genes to classify patients into different prognostic groups. 11, 19 In fact, the genetic testing should have a short turnaround time, inexpensive and reliable. Therefore, we did not search for other novel prognostic factors in our study and established a precise and simple nomogram based on the integration of the well-established clinical and molecular factors in the multivariate models. As a result, it was more important for clinical factors like WBC and age than molecular factors like ELN genotype and genes of IDH1 and DNMT3A mutations to contribute the predictive impact on OS and EFS, which was reflected in higher HR of clinical factors compared to the molecular factors. This result implied clinical factors are still taken as one of the most important predictors in AML risk classification. Therefore, we integrated these frequently mutated genes and well-established clinical variables to development the prediction nomogram. Notably, our nomogram showed reliable prediction of 3-year OS and EFS in the individual patient with CN-AML.
There are also some limitations in our study. First, the sample size was not enough large to identify all of the novel 
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mutated genes by WES. Second, our nomogram was only based on a single institutional experience. While the nomogram was internally validated using bootstrapped calibration and cross-validation, future studies are needed to externally validate the proposed nomogram. Third, these results were based on the retrospective study. In spite of some limitations, this is one of the few studies to develop a user-friendly, reliable prediction model for survivals in the large cohort of elderly patients with CN-AML.
In conclusion, we describe a nomogram that accurately predicts an individual survival according to clinical and molecular variables such as age, WBC, ENL favorable genotype, DNMT3A and IDH1 mutations and treatment protocols.
